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A Polymorphism in the Melanocortin 4 Receptor Gene (MC4R:
c.92C>T) Is Associated with Diabetes Mellitus in Overweight
Domestic Shorthaired Cats
Y. Forcada, A. Holder, D.B. Church, and B. Catchpole
Background: Feline diabetes mellitus (DM) shares many pathophysiologic features with human type 2 DM. Human
genome-wide association studies have identified genes associated with obesity and DM, including melanocortin 4 receptor
(MC4R), which plays an important role in energy balance and appetite regulation.
Hypothesis/Objectives: To identify single nucleotide polymorphisms (SNPs) in the feline MC4R gene and to determine
whether any SNPs are associated with DM or overweight body condition in cats.
Animals: Two-hundred forty domestic shorthaired (DSH) cats were recruited for the study. Of these, 120 diabetics were
selected (60 overweight, 60 lean), along with 120 nondiabetic controls (60 overweight and 60 lean). Males and females were
equally represented.
Methods: A prospective case-control study was performed. Genomic DNA was extracted from blood samples and used
as template for PCR amplification of the feline MC4R gene. The coding region of the gene was sequenced in 10 cats to
identify polymorphisms. Subsequently, genotyping by restriction fragment length polymorphism (RFLP) analysis assessed
MC4R:c.92C>T allele and genotype frequencies in each group of cats.
Results: No significant differences in MC4R:c.92C>T allele or genotype frequencies were identified between nondiabetic
overweight and lean cats. In the overweight diabetic group, 55% were homozygous for the MC4R:c.92C allele,
compared to 33% of the lean diabetics and 30% of the nondiabetics. The differences between the overweight diabetic and the
nondiabetics were significant (P < .01).
Conclusions and Clinical Importance: We identified a polymorphism in the coding sequence of feline MC4R that is
associated with DM in overweight DSH cats, similar to the situation in humans.
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Diabetes mellitus (DM) is one of the most commonfeline endocrinopathies.1 In the majority of dia-
betic cats, the disease is considered to result from similar
pathophysiologic mechanisms as human type 2 DM.1
Although the majority of cats suffer from type 2-like
DM, other types of DM do occur, resulting from a vari-
ety of underlying disorders that impact pancreatic beta
cell function (eg, pancreatitis)2 or that cause marked
insulin resistance (eg, growth hormone-secreting pitui-
tary tumor in acromegaly).3,4 DM is most commonly
seen in domestic shorthaired (DSH) cats. Burmese cats
are overrepresented in the diabetic population, whereas
other pure breeds seem underrepresented.5,6 These dif-
ferences in breed susceptibility suggest that genetic fac-
tors are involved in feline DM.
Two important factors may contribute to develop-
ment of type 2 DM in humans.7 First, the presence of
insulin resistance, which is considered to be primarily
a consequence of environmental factors such as exces-
sive caloric intake and decreased activity, plays a role.
Insulin resistance has been shown to be inherited in
several studies in Caucasians and other ethnic groups,
suggesting a genetic component.8–10 The second impor-
tant aspect is the presence of pancreatic b-cell dysfunc-
tion, in which the b-cells are less able to compensate
for an increase in functional demand and which, as a
consequence, undergo apoptosis more readily. b-cell
dysfunction has been linked to several genetic suscepti-
bility factors.11–13 In studies of humans, some individu-
als seem to have decreased insulin sensitivity and DM
even in the absence of environmental factors such as
obesity, whereas others have substantial insulin resis-
tance, but do not seem to progress to becoming overtly
diabetic. Thus, type 2 DM is a complex multifactorial
interaction, in which the combination of environment
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and genetic background plays a key role in the devel-
opment of the disease. Advances in molecular genetic
techniques, availability of the complete human genome
sequence, and single nucleotide polymorphism (SNP)
chips to allow performance of genome-wide association
studies (GWAS) have led to identification of genes
associated with type 2 DM in humans.14–23 To date,
there are no studies that have identified specific genes
that predispose cats to DM, although given a similar
pathophysiology and environmental risk factors, it
seems likely that feline DM could share a similar
genetic basis with the human disease.
The melanocortin 4 receptor (MC4R) gene, encoding
a transmembrane G-protein–coupled receptor, has
been implicated as a susceptibility gene in human DM
and obesity.24–27 This receptor is mainly expressed in
the hypothalamus and plays an important role in the
regulation of energy balance and appetite.28 In a situa-
tion of positive energy balance, MC4R is stimulated
by alpha -melanocyte stimulating hormone (a-MSH),
leading to a feeling of satiety. During periods of star-
vation, the activity of MC4R is inhibited by its inverse
antagonist, agouti-related protein (AGRP), leading to
a feeling of hunger.28 Mutations in this gene are the
most common single genetic cause of human obesity,
accounting for up to 6% of cases. A correlation
between MC4R mutations and human type 2 DM has
been shown in several studies,26,29,30 including a recent
meta-analysis, which showed an odds ratio (OR) of
1.10 (95% CI 1.07–1.13).31 Given the influence this
gene has on susceptibility to obesity and DM in
human beings and given the fact that obesity also
poses an important risk factor for DM1,32 in cats,
MC4R was considered to be a logical candidate gene
in the search for genetic factors predisposing to DM in
cats. The aim of this study was to confirm the
sequence of feline MC4R, to identify SNPs in its cod-
ing region, and to perform a case-control study to
detect a possible gene association with feline DM and
obesity.
Materials and Methods
Animals
Blood samples (EDTA or non-anticoagulated) from diabetic
cats were recruited via the UK Companion Animal Diabetes Regis-
ter, based at the Royal Veterinary College (RVC), from first opin-
ion veterinary practices in the UK, with samples submitted with a
standardized sample submission form (http://www.rvc.ac.uk/cic/
documents/GHsubmissionformV1328Jan10DL.pdf), that included
details of concurrent diseases and clinical signs, body weight and
body condition score (BCS) at and before diagnosis, diet and insu-
lin type and dose. The BCS assessment was carried out according
to the routinely used 9- and 5-point BCS systems, information
about how to assess the BCS of cats according to these systems
was included in the submission form. Blood samples from nondia-
betic cats were obtained from the RVC Genetic Archive, consisting
of retrospective residual samples (after completion of diagnostic
testing) from referral cases seen at RVC hospitals. Ethical approval
for sample collection had been obtained previously from the local
ethical committee. For the SNP discovery phase, 10 cats (5 Bur-
mese: 2 diabetic, 3 nondiabetic; 5 DSH: 3 diabetic, 2 nondiabetic)
were assessed. For the genotyping phase, a total of 240 DSH cats
were analyzed, consisting of 4 groups (n = 60 each; with males and
females equally represented) of overweight diabetic, lean diabetic,
overweight nondiabetic, and lean nondiabetic cats.
The diabetic cats were selected on the basis of the presence of
increased serum fructosamine concentration, persistent hypergly-
cemia, requiring insulin therapy, and having been diagnosed as
diabetic by the attending veterinarian for longer than 4 weeks.
Insulin growth factor-1 (IGF-1) was measured in all samples,
those cats with IGF-1 concentration<800 ng/mL were allocated
either to the overweight diabetic group (BCS > 4/5 or 5/9) or to
lean diabetic group (BCS ≤ 4/5 or 5/9). Those cats that were over-
weight before diagnosis and had lost weight before the diagnosis
of DM were included in the overweight group, because weight
loss is considered one of the landmark clinical signs of DM.
Those cats with known concurrent diseases that could have an
impact on body weight were excluded from the study. Based on
evaluation of medical records and available diagnostic informa-
tion, nondiabetic cats >9 years of age that had no clinical or bio-
chemical evidence of DM, specifically hyperglycemia or
glycosuria, were selected. Cats with clinical or biochemical evi-
dence of other diseases that could lead to changes in body weight
(eg, hyperthyroidism, renal disease, gastrointestinal disease, hepa-
tic disease) were excluded from the study. However, because these
samples were obtained from an archive of retrospective clinical
material, additional prospective diagnostic testing was not
performed. All of the nondiabetic cats were seen in a clinic staffed
by board-certified veterinary specialists. There were no known
familial relationships among any of the cats included in this study.
Feline MC4R SNP Discovery
The initial phase focused on resequencing the coding region of
the feline MC4R gene to identify SNPs. Genomic DNA (gDNA)
was extracted from EDTA blood samples or blood clots using a
blood genomic DNA extraction kit,a according to the manufac-
turer’s instructions. Feline MC4R-specific primers located in the 5′
untranslated region (UTR; Sense: 5′-CTCAGAACTTTCGG
GCAGAC-3′; starting at position -103) and in the 3′ UTR (Anti-
sense: 5′-ACCCATGCCTTACACAGAGG-3′; starting at position
1078) were designed according to the available feline MC4R
sequence (http://www.ensembl.org/Felis_catus/Info/Index; ENSF-
CAG00000006540. Assembly ASM18133v1, Genbank Assembly
ID: GCA_000181335.1). Polymerase chain reaction was performed
in 25 lL volumes using 0.1 lL of DNA polymerase (Immolase
DNA polymeraseb ) with 1 lL of gDNA as a template. Each reac-
tion also contained 13 lL of water, 5 lL of 59 PCR-enhancing
additive (Hi-Spec additiveb), 2.5 lL of ammonium sulfate buffer
(NH4 buffer
b), 1.25 lL MgCl2
b (2.5 mM final concentration),
0.25 lL 250 lM dNTPb, and 2 lL of primer mix (each at 20 pmol/
lL). Using a PCR cycler,c reactions were heated to 95°C for 10 min-
utes, followed by 30 cycles consisting of 94°C for 40 seconds, 65°C
for 30 seconds, and 72°C for 2 minutes, with a final extension step
at 72°C for 10 minutes. PCR products were separated by horizontal
gel electrophoresis using a 2% agarose gel and analyzed under
590 nm UV light.d Subsequently, DNA was extracted using a gel
extraction Kit (Genelute gel extraction Kite ) according to the man-
ufacturer’s instructions. Amplicons then were submitted for
sequencingf and compared to each other and with the reference
feline genome sequence using sequence analysis software .g
MC4R Genotyping by RFLP Analysis
Genomic DNA was extracted from EDTA blood or blood
clots and PCR performed as described in the SNP discovery sec-
tion. Amplified DNA then was purified using a PCR clean-up kit
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(Genelute PCR clean-up Kite), subjected to digestion using a
restriction enzyme (BstOI enzymeh), which recognizes a restric-
tion site (CC’(A/T)GG) incorporating the MC4R:c.92C allele,
absent in the MC4R:c.92T allele. The digestion reaction consisted
of 0.5 lL of BstOI restriction enzyme, 0.5 lL of BSA, 0.5 lL of
Buffer (Buffer Ch), and 3.5 lL of purified PCR product. Reac-
tions were incubated for 1 hour at 60°C in a water bath and ana-
lyzed by agarose gel electrophoresis as described above. In
samples in which gel interpretation was potentially ambiguous,
genotyping by RFLP was repeated using a higher DNA concen-
tration. If an unambiguous result still was not obtained, manual
sequencing was performed.
Statistical Analysis
Statistical analysis was performed using SPSS software pack-
age.i The Mann–Whitney U-test was used to analyze non para-
metric variables. The Pearson’s two-tailed chi-squared test was
used to compare MC4R:c.92C>T SNP genotype and allele fre-
quencies among groups, and the OR with 95% confidence inter-
val (CI) was calculated. Bonferroni correction was applied for
multiple group comparisons. Significance was considered at
P < .01.
Results
Animals
The median age of the overweight diabetic cats was
12 years (range, 6–18 years); the median weight was
6.6 kg (range, 5.1–10.0 kg). The median age of the
lean diabetic cats was 13 years (range, 5–18 years); the
median weight was 4.15 kg (range, 2.6–6.0 kg).
For the overweight nondiabetic group (30 male,
30 female), the mean age was 12 years (range,
9.1–20 years) and the median weight 5.7 kg (range,
3.4–8.3 kg). For the lean nondiabetic group (30 male,
30 female), the median age was 13.9 years (range,
9–19 years) and the mean weight 3.9 kg (range,
2.5–5.7 kg).
The age difference between diabetics and nondiabet-
ics was not statistically significant (P = .074), whereas
the obese cats were significantly heavier than the lean
cats (P < .001).
Polymorphisms in Feline MC4R
Initial sequencing results showed the presence of 3
polymorphisms. A non synonymous SNP in position
92 of the coding sequence (MC4R:c.92C>T) was found
in the DSH cats only and led to an amino acid change
from leucine to proline in the protein sequence. Fig-
ure 1 shows the sequencing results from the initial
SNP discovery phase (10 cats) and represents the frag-
ment of the coding sequence of MC4R where the non
synonymous SNP was detected. Two additional synon-
ymous SNPs (MC4R:c297C>T and MC4R:c303C>T)
also were present in both the DSH and the Burmese
cats.
MC4R:c.92C Homozygous Genotype in Obese
Diabetic DSH Cats
A case-control study was performed, focusing on the
MC4R:c.92C>T SNP, to determine whether there was
any association with increased body weight or DM.
The RFLP assay was found to be a rapid and simple
test to identify MC4R genotypes in cats (Fig 2). In the
2 nondiabetic groups, there was no significant differ-
ence in allele or genotype frequencies comparing the
overweight and lean cats (Table 1), and data from
these cats subsequently were combined into a single
nondiabetic control group. There were no differences
in allele frequencies, comparing the lean and over-
weight diabetic groups (n = 60 each group) and the
nondiabetic control group (n = 120) (Table 2). How-
ever, in the overweight diabetic group (n = 60), the
majority of cats (55%) were homozygous for the
MC4R:c.92C allele (Table 2) compared with the nondi-
abetic control group (n = 120), where 30% were
homozygous C, a difference that was statistically sig-
nificant (P = .002). In contrast, there was no difference
Fig 1. Initial single nucleotide polymorphism (SNP) discovery phase, fragment of the coding sequence of feline MC4R in which the
non synonymous SNP was detected (purple circle). This SNP (MC4R:c.92 C>T) was detected exclusively in domestic shorthaired (DSH)
cats and leads to leucine being replaced by proline in the translated protein. DMBURM1, diabetic Burmese cat1; DMBURM2, diabetic
Burmese cat 2; DMDSH1, diabetic DSH cat 1; DMDSH2, diabetic DSH cat 2; DMDSH3, diabetic DSH cat 3; NONDMBURM1, non-
diabetic Burmese cat 1; NONDMBURM2, nondiabetic Burmese cat 2; NONDMDSH1, nondiabetic DSH cat 1; NONDMDSH2, nondi-
abetic DSH cat 2; NONDMDSH3, nondiabetic DSH cat 3; A, adenine; C, cytosine; G, guanine; T, thymine; Y, heterozygous cats
(C and T alleles).
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in genotype distribution when comparing the lean dia-
betic cats (n = 60) with the nondiabetic cats (n = 120)
(P = .7) and when comparing lean diabetics (n = 60)
with the obese diabetic cats (n = 60) (P = .02). Over-
weight cats that were homozygous for the mutation
had a statistically significantly higher OR for DM of
3.67 (95% CI, 1.68–7.95, P = .0007) when compared
to nonhomozygous obese cats.
Discussion
The present study demonstrates that a genetic factor
(homozygosity for the MC4R:c.92C allele) may be
associated with DM in overweight DSH cats. Three
SNPs were identified in the feline MC4R coding
sequence, with 2 of these (MC4R:c297C>T and
MC4R:c303C>T) representing synonymous changes
and therefore less likely to impact protein structure or
function than the non synonymous SNP (MC4R:
c.92C>T). Additional polymorphisms may occur
upstream (ie, in the gene regulatory regions) or down-
stream of the coding region, but these areas were not
investigated in the current study. Because only 10 cats
were evaluated in the SNP discovery phase, it is possi-
ble that other less common SNPs are present in feline
MC4R. However, because only SNPS with a minor
allele frequency >0.1 are normally used in case-control
association studies, relatively rare SNPs would not be
deemed suitable and therefore were excluded from
subsequent genetic analysis.
Table 2. Association of MC4R:c.92 CC homozygous
genotype with diabetes in obese DSH cats.
CC CT/TT Total
Nondiabetica,b 30% (n = 36) 70% (n = 84) 120
Overweight diabetica,c 55% (n = 33) 45% (n = 27) 60
Lean diabeticb,c 33% (n = 20) 66% (n = 40) 60
MC4R, melanocortin 4 receptor; DSH, domestic shorthaired;
C, cytosine; T, thymine.
aPearson’s chi-square comparison of CC genotype and CT/TT
genotypes between nondiabetic DSH cats and overweight diabetic
DSH cats, P = .002.
bPearson’s chi-square comparison of CC genotype and CT/TT
genotypes between nondiabetic DSH cats and lean diabetic DSH
cats, P = .7.
cPearson’s chi-square comparison of CC genotype and CT/TT
genotypes between overweight diabetic DSH cats and lean
diabetic DSH cats, P = .02.
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Fig 2. Representative BstOI restriction fragment length polymorphism (RFLP) results. The lane to the left of each digested polymerase
chain reaction (PCR) product corresponds to aliquots of the PCR product before digestion (see lanes 2, 4, 6, 8, 10, 12). Lane 1: DNA
ladder I (0.2–10 kb). Homozygous C cats have restriction sites in positions 151 and 315 of the PCR product, resulting in 1 fragment of
885 bp and 2 fragments of smaller size: 150 and 165 bp (eg, lanes 3 and 9). Homozygous T cats have 1 restriction site at position 315 of
the PCR product, resulting in 1 fragment of 885 bp and 1 fragment of 315 bp (eg, lane 13); Heterozygous cats showed 1 fragment of
885 bp, 1 fragment of 315 bp, and 2 smaller fragments of 150 and 165 bp (eg, lanes 5, 7, and 11). L, ladder; U, undigested; D, digested.
Table 1. Summary of MC4R:c92T>C RFLP results for control cats.
Genotype
Frequency
Genotype
Frequency
Allele Frequency
Allele
FrequencyCC CT/TT C T
Lean control 0.35 (n = 21) 0.65 (n = 39) P = .19 0.61 0.39 P = .31
Overweight control 0.25 (n = 15) 0.75 (n = 45) 0.53 0.47
MC4R, melanocortin 4 receptor; RFLP, restriction fragment length polymorphism; C, cytosine; T, thymine.
Statistical analysis performed using two-tailed Pearson’s chi-square test. Significance established at a P value <.01.
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Previous studies in humans have shown that muta-
tions in the MC4R gene are associated with obesity,
which increases the risk of those individuals developing
type 2 DM.26,29–31 The current study failed to demon-
strate any association between the MC4R:c.92C>T
polymorphism and overweight body condition in non-
diabetic DSH cats, but the sample size was relatively
small. Rather than having a direct effect on regulating
satiety and food intake and consequently influencing
body weight, these results suggest that this polymor-
phism may be associated with progression to overt
DM in overweight cats. Alternatively, this polymor-
phism might be in linkage disequilibrium with another
causative polymorphism or mutation elsewhere in the
genome.
Under physiologic conditions, MC4R is constitu-
tively active, leading to an appetite suppression signal
until negative energy balance develops. At this time, a
decrease in leptin concentration and a subsequent
increase in the inverse agonist AGRP occur. AGRP
binding inactivates the MC4R receptor, leading to an
increase in appetite.28 Functional studies performed in
humans have demonstrated that mutations that influ-
ence the amino acid sequence in the N-terminal region
of the protein generate receptors that are unable to
maintain their constitutive activity, leading to
decreased appetite suppression and increased food
intake.33 In addition, several studies have evaluated
the role of MC4R in energy metabolism, but conflict-
ing results have been reported.34–37 Notwithstanding
discrepancies in the published literature, studies in
mice have indicated that mutations of the MC4R
receptor can lead to a reduction in metabolic rate,
indicating that this receptor might play additional
roles in energy metabolism and there may be interspe-
cies differences in receptor function. The non synon-
ymous MC4R:c92C>T SNP identified in DSH cats
causes an amino acid change from leucine to proline
at amino acid position 30.
The GWAS of human type 2 DM, which identified
MC4R as a susceptibility gene, involved relatively large
numbers of cases and controls.25,38 Unfortunately,
such large-scale genetic studies are difficult to replicate
in companion animals, with the result that many stud-
ies are relatively underpowered. Regardless, GWAS of
several diseases of dogs have yielded results, even with
relatively low numbers, when performed within
breeds.39–41 This is likely to be similar for genetic stud-
ies of cats, if performed within relatively inbred pedi-
gree populations, but in the DSH cat population,
which is more outbred, larger sample sizes are likely to
be required for case-control genotyping studies. Never-
theless, a significant difference was found in the cur-
rent study, even with relatively small numbers of DSH
cats, suggesting that this gene might play a major role
in susceptibility to DM in overweight cats.
The current study has a number of limitations. The
diabetic cases and controls were breed- and sex-
matched, but not age-matched. Older cats were proac-
tively recruited as controls to decrease the chances of
including cats that might become diabetic later in life.
Previous studies have demonstrated that the risk of
developing DM in cats increases with age,42 and there-
fore, even though the nondiabetic (overweight and
lean) populations were older than the diabetic popula-
tions, this is likely to be beneficial rather than detri-
mental. BCS information was obtained from all cats,
including information about BCS before diagnosis
when available. Because one of the landmark clinical
signs of DM is weight loss, some cats that were over-
weight before developing the disease may have been
included in the lean group. Although an attempt was
made to exclude cats that had concurrent diseases that
could alter body weight, this was not always possible.
This could have changed the results of the study. The
overall prevalence of the SNP in the diabetic group
(lean and obese), however, still is significantly higher
than in the nondiabetic group. Given the effect that
MC4R mutations have on appetite regulation in
humans, it would have been valuable to have obtained
information about each cat in terms of appetite and
food intake. Although some of this information was
available for some of the cats, it proved difficult to
incorporate these data into the analysis or selection
criteria because of the subjectivity of evaluating food
intake and appetite, particularly in multi-cat house-
holds and when different diets and feeding regimes (eg,
ad libitum or not) were being used.
The current findings are of interest not only in
advancing our knowledge of the pathogenesis of feline
DM but also in terms of clinical relevance. Thus,
MC4R genotyping of overweight cats might be useful
in estimating the relative risk of the cat progressing to
overt DM, given an OR of 3.67 comparing the over-
weight diabetic group with the overweight nondiabetic
group. Because feline DM is likely to represent a com-
plex genetic disorder, identification of other suscepti-
bility genes is warranted and, if confirmed to be
present, a test based on genetic profiling of multiple
genes potentially could be used to establish an overall
genetic risk for development of DM. This might then
be useful for identifying cats with a greater risk of
developing the disease, so that preventative measures
(eg, dietary management) could be implemented to
decrease other risk factors (eg, development of obesity)
that might precipitate disease in a genetically susceptible
individual.
In conclusion, we have demonstrated that a genetic
factor may influence susceptibility to DM in cats. The
feline MC4R:c.92C>T polymorphism may be involved
in progression to overt DM in overweight cats, but it
remains to be established whether or not a causal rela-
tionship is present, or if it is simply an association. If
the polymorphism does have functional consequences,
this does not seem to be directly related to increased
susceptibility to overweight body condition and might,
instead, play a role in glycemic control in the presence
of insulin resistance or influence pancreatic beta cell
function in response to chronic hyperglycemia. Func-
tional studies to investigate the physiologic relevance
of this polymorphism and GWAS to identify other
susceptibility genes for feline DM are warranted.
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Footnotes
a GenElute blood genomic DNA extraction kit; Sigma, Poole,
UK
b Bioline, London, UK
c Eppendorf Master Cycler; Eppendorf AG, Hamburg, Germany
d ImageMaster VDS; Pharmacia Biotech/GE Healthcare, Buck-
inghamshire, UK
e Sigma-Aldrich, Dorset, UK
f GATC Biotech Ltd The London BioScience Innovation Centre,
London, UK
g Genedoc software (Nicholas et al, 1997), http://www.nrbsc.org/
gfx/genedoc/index.html
h Promega, Southampton, UK
i SPSS software, IBM, Portsmouth, UK
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